FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

120 letters match. Newest first.

  1. Newman Clinic, PLLC dba Newman Clinic

    FDA told Newman Clinic its website misbranded compounded semaglutide and tirzepatide with false and misleading claims.

    Medium
  2. NewSelf Limited dba NewSelf

    FDA warns NewSelf over misleading website claims for compounded semaglutide and tirzepatide, including false compounder and FDA-approval implications.

    Low
  3. 24HrDoc, Inc. dba 24HrDoc

    FDA says 24HrDoc's website misbrands compounded semaglutide and tirzepatide with false claims that it compounds them and that they match Ozempic, Wegovy, Mounjaro, Zepbound.

    Medium
  4. Alan Health Technologies Inc. dba Alan

    FDA warns Alan Health Technologies over website falsely labeling compounded semaglutide and tirzepatide as Alan-made.

    Low
  5. Dripgym Mobile Parent, LLC dba Amp Health

    FDA warned Amp Health that its website misbranded compounded semaglutide and tirzepatide with false maker and approval-implying claims.

    Low
  6. Belle Health LLC dba Belle

    FDA warned Belle Health that its website falsely suggests Belle compounds semaglutide and tirzepatide, making the drugs misbranded.

    Low
  7. Bliv Wellness LLC dba Bliv

    FDA warns Bliv Wellness that its website falsely suggests it compounds semaglutide and tirzepatide, making the drugs misbranded.

    Medium
  8. BluefitMD

    FDA warned BluefitMD that its website falsely labels compounded semaglutide and tirzepatide as its own and as FDA-approved.

    Low
  9. Deluxe IV Aesthetics PLLC dba Deluxe IV and Aesthetics

    FDA warned Deluxe IV and Aesthetics over misleading website claims for compounded semaglutide and tirzepatide, including implying FDA approval.

    Low
  10. Aspen Aesthetics dba Fifty 410

    FDA warns Fifty 410 over misleading website claims for compounded semaglutide and tirzepatide, including implied compounding and 'clinically proven' claims.

    Low
  11. FitRX, LLC dba FitRx

    FitRx's website misbranded compounded semaglutide and tirzepatide with false and misleading claims, FDA says.

    Medium
  12. Genesis Health International Inc. dba Genesis

    FDA warns Genesis over misleading website claims for compounded semaglutide and tirzepatide.

    Low
  13. Dynamic Stem Cell Therapy

    FDA warned Dynamic Stem Cell Therapy that its umbilical cord-derived stem cell product is an unapproved, unlicensed, misbranded biological drug.

    High risk
  14. ExThera Medical Corporation

    ExThera shipped Seraph 100 blood filters for compassionate use without FDA approval and promoted them as approved.

    High risk
  15. MedisourceRx

    MedisourceRx failed to report a serious adverse event and had inadequate procedures, so its compounded drugs lost legal exemptions.

    Medium
  16. Elanco Animal Health USA

    FDA says Elanco's Pradalex ads misbrand the livestock antibiotic by claiming first-line use and "all relevant pathogen" coverage.

    Medium
  17. Genetrace

    FDA warned Genetrace that its HIV dried blood spot self-collection kit is unapproved and misbranded.

    High risk
  18. Genovate

    FDA warns Genovate over selling an unapproved HIV dried-blood-spot self-collection kit without marketing authorization.

    High risk
  19. Agebox Inc.

    Agebox Inc. sells iKids-Growth children's supplements containing the undeclared, unapproved drug ibutamoren, making them unapproved and misbranded drugs.

    High risk
  20. Exela Pharma Sciences LLC

    Unapproved New Drug/Compounding/Misbranding